Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
May 23, 2017
• Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer
Leiden, The Netherlands, May 23, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).
A poster presentation will be held by Winald Gerritsen MD, PhD., one of the Principle Investigators of the CervISA study, on Thursday, June 3, 2017:
“Poster Session Gynecologic Cancer”: 1:15PM – 4:45PM
The data will be based on the abstract titled "Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival" (abstract no. 5525). The Company intends to publish the data in a peer-reviewed journal later this year.
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In addition, ISA has begun to develop MyISA®, a personalized SLP® immunotherapy, targeting tumor-specific, mutation-derived neo-antigens. These SLP®s are based on the analysis of immunogenic DNA mutations in a tumor sample, and designed and synthesized for each individual patient.
ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-positive solid tumors (such as small cell carcinoma of head and neck SCCHN) and anal intraepithelial neoplasia (AIN). A clinical Phase II combination trial with ISA101 and Nivolumab is completed and will soon be reported by the MD Anderson Cancer Center in the US. Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
SLP®, AMPLIVANT® and MyISA® are registered trademarks in Europe.
Contact & Media Inquiries:
Dr. Ludger Wess, Ines-Regina Buth
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68
Contact // Kontakt akampion Newswire:
Dr. Ludger Wess
Managing Partner, akampion
T: +49 (0)40 88 16 59 64
F: +49 (0)40 88 16 59 65
Managing Partner, akampion
T: +49 (0)30 23632768
F: +49 (0)30 23632769